192 related articles for article (PubMed ID: 20807602)
21. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.
Nicklin SA; Buening H; Dishart KL; de Alwis M; Girod A; Hacker U; Thrasher AJ; Ali RR; Hallek M; Baker AH
Mol Ther; 2001 Sep; 4(3):174-81. PubMed ID: 11545607
[TBL] [Abstract][Full Text] [Related]
22. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.
Trepel M; Stoneham CA; Eleftherohorinou H; Mazarakis ND; Pasqualini R; Arap W; Hajitou A
Mol Cancer Ther; 2009 Aug; 8(8):2383-91. PubMed ID: 19671758
[TBL] [Abstract][Full Text] [Related]
23. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.
Raake PW; Hinkel R; Müller S; Delker S; Kreuzpointner R; Kupatt C; Katus HA; Kleinschmidt JA; Boekstegers P; Müller OJ
Gene Ther; 2008 Jan; 15(1):12-7. PubMed ID: 17943147
[TBL] [Abstract][Full Text] [Related]
24. High-Throughput
Westhaus A; Cabanes-Creus M; Rybicki A; Baltazar G; Navarro RG; Zhu E; Drouyer M; Knight M; Albu RF; Ng BH; Kalajdzic P; Kwiatek M; Hsu K; Santilli G; Gold W; Kramer B; Gonzalez-Cordero A; Thrasher AJ; Alexander IE; Lisowski L
Hum Gene Ther; 2020 May; 31(9-10):575-589. PubMed ID: 32000541
[TBL] [Abstract][Full Text] [Related]
25. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.
White SJ; Nicklin SA; Büning H; Brosnan MJ; Leike K; Papadakis ED; Hallek M; Baker AH
Circulation; 2004 Feb; 109(4):513-9. PubMed ID: 14732747
[TBL] [Abstract][Full Text] [Related]
26. Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.
Kia A; Przystal JM; Nianiaris N; Mazarakis ND; Mintz PJ; Hajitou A
Mol Cancer Ther; 2012 Dec; 11(12):2566-77. PubMed ID: 23053496
[TBL] [Abstract][Full Text] [Related]
27. Systemic Delivery of Adeno-Associated Viral Vectors in Mice and Dogs.
Wasala LP; Hakim CH; Yue Y; Yang NN; Duan D
Methods Mol Biol; 2019; 1937():281-294. PubMed ID: 30706404
[TBL] [Abstract][Full Text] [Related]
28. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
[TBL] [Abstract][Full Text] [Related]
29. Enhancing transduction of the liver by adeno-associated viral vectors.
Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
[TBL] [Abstract][Full Text] [Related]
30. Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.
Campbell S; Suwan K; Waramit S; Aboagye EO; Hajitou A
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29690504
[TBL] [Abstract][Full Text] [Related]
31. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.
Shi W; Bartlett JS
Mol Ther; 2003 Apr; 7(4):515-25. PubMed ID: 12727115
[TBL] [Abstract][Full Text] [Related]
32. Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.
Hösel M; Huber A; Bohlen S; Lucifora J; Ronzitti G; Puzzo F; Boisgerault F; Hacker UT; Kwanten WJ; Klöting N; Blüher M; Gluschko A; Schramm M; Utermöhlen O; Bloch W; Mingozzi F; Krut O; Büning H
Hepatology; 2017 Jul; 66(1):252-265. PubMed ID: 28318036
[TBL] [Abstract][Full Text] [Related]
33. [Developments in gene delivery vectors for ocular gene therapy].
Khabou H; Dalkara D
Med Sci (Paris); 2015 May; 31(5):529-37. PubMed ID: 26059304
[TBL] [Abstract][Full Text] [Related]
34. Bacteriophage-mediated therapy of chondrosarcoma by selective delivery of the tumor necrosis factor alpha (TNFα) gene.
Chongchai A; Waramit S; Suwan K; Al-Bahrani M; Udomruk S; Phitak T; Kongtawelert P; Pothacharoen P; Hajitou A
FASEB J; 2021 May; 35(5):e21487. PubMed ID: 33811705
[TBL] [Abstract][Full Text] [Related]
35. Vectrology of adeno-associated viruses (AAV).
Skubis-Zegadło J; Stachurska A; Małecki M
Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444
[TBL] [Abstract][Full Text] [Related]
36. Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.
Denby L; Nicklin SA; Baker AH
Gene Ther; 2005 Oct; 12(20):1534-8. PubMed ID: 15944729
[TBL] [Abstract][Full Text] [Related]
37. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.
Rabinowitz JE; Rolling F; Li C; Conrath H; Xiao W; Xiao X; Samulski RJ
J Virol; 2002 Jan; 76(2):791-801. PubMed ID: 11752169
[TBL] [Abstract][Full Text] [Related]
38. AAV6 Vector Production and Purification for Muscle Gene Therapy.
Halbert CL; Allen JM; Chamberlain JS
Methods Mol Biol; 2018; 1687():257-266. PubMed ID: 29067669
[TBL] [Abstract][Full Text] [Related]
39. Evolving phage vectors for cell targeted gene delivery.
Larocca D; Burg MA; Jensen-Pergakes K; Ravey EP; Gonzalez AM; Baird A
Curr Pharm Biotechnol; 2002 Mar; 3(1):45-57. PubMed ID: 11883506
[TBL] [Abstract][Full Text] [Related]
40. Adeno-associated viral vectors and their redirection to cell-type specific receptors.
Michelfelder S; Trepel M
Adv Genet; 2009; 67():29-60. PubMed ID: 19914449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
